Compare Franco-Nevada Corporation (FNV) vs MiniMed Group Inc. Common Stock (MMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs MiniMed Group Inc. Common Stock — how do they compare? Franco-Nevada Corporation trades at $236.47 (market cap $46.80B), while MiniMed Group Inc. Common Stock trades at $16.74 (market cap $5.18B). The key difference: Franco-Nevada Corporation is far larger — about 9× MiniMed Group Inc. Common Stock's market cap, and Franco-Nevada Corporation pays a 0.72% dividend while MiniMed Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and MiniMed Group Inc. Common Stock for 6 Days on average.
| FNV | MMED | |
|---|---|---|
Market Cap | $46.80B | $5.18B |
Volume | 310,692 | 33,606,669 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $23.84 |
52-Week Low | $183.97 | $10.80 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $45.79B | $4.98B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
MMED trades at $18.40, down 2.13% today, with technical indicators showing bearish momentum. The company reported revenue growth to $2.72B in 2025 but posted a net loss of -$250M. Recent news highlights Medtronic's exchange offer completion and MiniMed's new product launches. Analyst consensus remains strongly bullish with 100% buy ratings and a $25.73 price target, representing 40% upside potential from current levels.
Despite negative profitability metrics and bearish technical signals, MMED maintains strong analyst support and revenue growth trajectory. Key risks include persistent net losses, high short interest, and execution challenges in the competitive diabetes technology market. The stock offers potential upside if new product cycles drive margin improvement and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About MiniMed Group Inc. Common Stock
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →
